---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-000821"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2024-01-03T23:59:59+00:00"
generated_at: "2026-06-07T04:35:40.758018+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech closes registered direct offering of 3.3M units at $3.33 for $11M gross proceeds

## Summary
- Offered 3,303,305 units at $3.33 each, each consisting of one share of common stock and one warrant.
- Warrants have exercise price of $3.21 per share, immediately exercisable, expiring five years from issuance.
- Gross proceeds approximately $11.0 million before placement agent fees and expenses.
- Net proceeds to be used for operations, including R&D, clinical trials, acquisitions, and working capital.
- Roth Capital Partners acted as exclusive placement agent with a 7% commission; offering closed on January 3, 2024.

## SEC filing metadata
- accession: 0001104659-24-000821
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2024-01-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000110465924000821/0001104659-24-000821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000110465924000821/tm241522d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-000821
- JSON: https://secwatch.observer/filing/0001104659-24-000821.json
- Plain text: https://secwatch.observer/filing/0001104659-24-000821.txt

## Key facts
- Material Agreements
  Fortress Biotech, Inc. entered into Securities Purchase Agreement with the purchasers valued at approximately $11.0 million (effective 2023-11-10).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the purchasers
  - Value: approximately $11.0 million
  - Effective: 2023-11-10
  source text: a Securities Purchase Agreement (the “ Securities Purchase Agreement ”), dated November 10, 2023, between the Company and the purchasers party thereto.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000110465924000821/0001104659-24-000821-index.htm
- Material Agreements
  Fortress Biotech, Inc. entered into Placement Agency Agreement with Roth Capital Partners, LLC (effective 2023-12-29).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Roth Capital Partners, LLC
  - Effective: 2023-12-29
  source text: a Placement Agency Agreement, dated as of December 29, 2023, between the Company and Roth (the “ Placement Agency Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000110465924000821/0001104659-24-000821-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.